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1. Introduction  
Hypertension is a common condition, which affects approximately 25% of the adult 
population, with a higher prevalence in black (African origin) people. Presently it is 
considered to affect 1 billion people worldwide. Essential or primary hypertension, also 
known as hypertension of unknown cause, constitutes approximately 90-95% of cases of 
hypertension. It is a major risk factor for cardiovascular and cerebrovascular diseases and is 
responsible for most deaths worldwide. Risk factors for hypertension include family history, 
ageing, lifestyle (e.g. stress, diet, alcohol), and obesity.  
The prevalence of hypertension in Cuba according to the 2010 statistics of the Ministry of 
Health is 202.7/1000 (http://files.sld.cu/hta/files/2011/09/prevalencia-de-hta.pdf), but it 
is considered to be underestimated. An epidemiological study conducted in 1995 in urban 
areas had revealed a prevalence of 30.6%. 
As the population ages, the prevalence of hypertension is expected to increase even further, 
making it very important to establish more effective preventive measures. The  Framingham 
Heart Study has implied that individuals who are normotensive at age 55 have a 90 percent 
lifetime risk for developing hypertension. It has been well established that the relationship 
between blood pressure (BP) and risk of cardiovascular events is continuous, consistent, and 
independent of other risk factors. The higher the BP, the greater the chance to suffer from 
heart attack, heart failure, stroke, and kidney disease (Chobanian et al, 2003). 
Primary hypertension results from the interplay of internal derangements (primarily in the 
kidney) and the external environment. Sodium, the main extracellular cation, has long been 
considered the pivotal environmental factor in the disorder. Many pathophysiologic factors 
have been implicated in the genesis of essential hypertension: increased sympathetic 
nervous system activity, perhaps related to heightened exposure or response to psychosocial 
stress; overproduction of sodium-retaining hormones and vasoconstrictors; long-term high 
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sodium intake; inadequate dietary intake of potassium and calcium; increased or 
inappropriate renin secretion with resultant increased production of angiotensin II and 
aldosterone; deficiencies of vasodilators, such as prostacyclin, nitric oxide, and the 
natriuretic peptides; alterations in expression of the kallikrein–kinin system that affect 
vascular tone and renal salt handling; abnormalities of resistance vessels, including selective 
lesions in the renal microvasculature; diabetes mellitus; insulin resistance; obesity; increased 
activity of vascular growth factors; alterations in adrenergic receptors that influence heart 
rate, iontropic properties of the heart, and vascular tone; and altered cellular ion transport. 
The concept that structural and functional abnormalities in the vasculature, including 
endothelial dysfunction, increased oxidative stress, vascular remodeling, and decreased 
compliance, may antedate hypertension and contribute to its pathogenesis has gained 
support in recent years (Adrogue & Madias, 2007; Oparil et al, 2003). 
Hypertension has been extensively recognized as a highly prevalent risk factor for 
cardiovascular disease, becoming an increasingly common health problem worldwide because 
of increasing longevity and prevalence of contributing factors such as obesity, physical 
inactivity and an unhealthy diet. The current prevalence in many developing countries, 
particularly in urban societies, is already as high as those seen in developed countries. It also 
plays a major etiologic role in the development of cerebrovascular disease and renal failure. 
In the 2007 European Guidelines for the management of arterial hypertension, it is 
recognized that although cardiovascular morbidity and mortality bear a continuous 
relationship with both systolic and diastolic blood pressures; the relationship has been 
reported to be less steep for coronary events than for stroke, which has been labelled as the 
most important ‘‘hypertension related’’ complication. The fact that hypertension is 
considered a major risk factor for an array of cardiovascular and related diseases, and the 
wide prevalence of high BP in the population, led to the World Health Organization (WHO) 
listing high BP as the first cause of death worldwide (Mancia et al, 2007). 
Taking into account the very high prevalence of hypertension in the general population and 
its deleterious consequences, signs of organ involvement are sought carefully, and a large 
body of evidence is now available on the crucial role of subclinical organ damage. For 
cardiovascular and renal diseases this has been well established, as the techniques applied 
are widely available; but the detection of initial brain deterioration, requires the use of 
imaging techniques, whose availability and costs do not allow indiscriminate use by general 
medical practitioners. 
In this chapter we present an update on the current status of markers employed for the early 
detection of brain damage in essential hypertension, and our experience in relation to the 
use of serum biochemical markers of brain injury.   
2. Target organ damage in hypertension 
The consequences of hypertension have been in constant debate since the mid 20th century. 
The most renowned consequences are probably those related with its role as a risk factor for 
myocardial infarction, heart failure, stroke and kidney disease, although it has also been 
involved in the development of vascular cognitive impairment and vascular dementia [Mancia 
et al, 2007; Chobanian et al, 2003; Henskens et al, 2009]. Chronic hypertension affects the 
cardiac and vascular systems, and various organs, especially the brain, kidney, and retina.  
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Table 1 shows the Position Statement of the 2007 European Guidelines for the Management 
of Arterial Hypertension concerning the detection of subclinical organ damage in 
hypertensive patients. 
 
Organ damage Techniques for detection 
Heart 
 
Left ventricular hypertrophy 
Angina or prior myocardial infarction 
Prior coronary revascularization 
Heart failure 
Electrocardiography should be part of all routine 
assessment of subjects with high BP in order to 
detect left ventricular hypertrophy, patterns of 
‘‘strain’’, ischemia and arrhythmias. 
Echocardiography is recommended when a more 
sensitive detection of left ventricular hypertrophy 
is considered useful. Geometric patterns can be 
defined echocardio-graphically, of which 
concentric hypertrophy carries the worse 
prognosis. Diastolic dysfunction can be evaluated 
by transmitral Doppler. 
Brain 
 
Stroke or transient ischemic attack 
White matter hyperintensities (WMH) 
Silent brain infarcts, lacunar infarctions, 
microbleeds and white matter lesions are not 
infrequent in hypertensives, and can be detected 
by MRI or CT. Availability and costs do not allow 
indiscriminate use of these techniques. In elderly 
hypertensives, cognitive tests may help to detect 
initial brain deterioration. 
Chronic kidney disease 
 
  GFR below 60 ml/min per 1.73 m2 
  (corresponding approximately to a         
  creatinine of >1.5 mg/dL in men or 
  >1.3 mg/dL in women), 20 or (2) the  
  presence of albuminuria (>300 mg/day 
  or 200 mg albumin/g creatinine) 
Diagnosis of hypertension-related renal damage 
is based on a reduced renal function or an 
elevated urinary excretion of albumin.  
Estimation from serum creatinine of glomerular 
filtration rate (MDRD formula, requiring age, 
gender, race) or creatinine clearance (Cockroft–
Gault formula, requiring also body weight) 
should be routine procedure.  
Urinary protein should be sought in all 
hypertensives by dipstick. In dipstick negative 
patients low grade albuminuria 
(microalbuminuria) should be determined in spot 
urine and related to urinary creatinine excretion. 
Peripheral arterial disease 
Ultrasound scanning of carotid arteries is 
recommended when detection of vascular 
hypertrophy or asymptomatic atherosclerosis is 
deemed useful. Large artery stiffening (leading to 
isolated systolic hypertension in the elderly) can be 
measured by pulse wave velocity. It might be more 
widely recommended if its availability were greater.  
A low ankle-brachial BP index signals advanced 
peripheral artery disease. 
Retinopathy 
Fundoscopy – Examination of eye grounds is 
recommended in severe hypertensives only. Mild 
retinal changes are largely non-specific except in 
young patients. Hemorrhages, exudates and 
papilloedema, only present in severe 
hypertension, are associated with increased CV 
risk. 
Table 1. Detection of subclinical organ damage in hypertensive patients 
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The brain is an early target for organ damage due to high BP, which is the major modifiable 
risk factor in men and women for ischemic and hemorrhagic stroke, as well as small vessel 
disease predisposing to lacunar infarction, white matter lesions (WML), and cerebral 
microbleeds, which are frequently silent. Arterial hypertension has been related to the 
development of brain damage, dementia, other CNS dysfunctions and even to milder forms 
of brain injury (Al-Sarraf and Philip, 2003; Amenta et al, 2003). The mechanisms underlying 
brain damage are thought to be a consequence of oxidative stress, inflammation and a defect 
in blood-brain barrier permeability (Al-Sarraf & Philip, 2003, Ishida et al, 2006; Poulet et al, 
2006; Ueno et al, 2004). 
Currently, hypertension guidelines mainly recognize the heart and kidneys as the crucial 
target organs affected by high blood pressure. Nevertheless, recently Henskens et al (2009) 
showed that silent cerebrovascular disease (identified with brain MRI) is a more frequent 
finding in hypertensive patients than cardiorenal damage.  On the other hand, 
cardiovascular risk in these patients equaled that of patients with cardiorenal involvement 
and was significantly higher than that observed in patients without any hypertensive target-
organ damage. This work suggested that the addition of silent cerebrovascular disease as a 
marker of hypertensive target-organ damage, apart from measures of cardiorenal 
involvement, refined the identification of patients at increased risk of cardiovascular and 
cerebrovascular complications. Thus, extending the search for hypertensive target-organ 
damage to other organs such as the brain might not only refine risk stratification, but might 
also optimize antihypertensive therapy. According to the results obtained by Henskens et al, 
35% of the patients free of organ damage had actually silent brain damage. If we take into 
account that in the current guidelines for the management of arterial hypertension, the 
decision of drug intervention depends largely on the presence of target-organ involvement, 
these patients would be receiving suboptimal treatment.  
The Reappraisal of the European Guidelines on hypertension management (Mancia et al, 
2009) reports that, in a group of 192 untreated hypertensive patients (aged 18–90 years) 
without overt cardiovascular disease, silent cerebrovascular lesions (WML, lacunar infarcts, 
cerebral microbleeds) were more prevalent (44%) than cardiac (21%) and renal (26%) 
subclinical damage and frequently occur in the absence of other signs of organ damage. On 
the other hand, 58% of patients with demonstrable cardiac or renal damage or both had 
silent cerebrovascular lesions. 
Stroke is the main neurological cause of mortality and the third most common cause of 
death worldwide, and hypertension is still it´s most important risk factor. In clinical trials, 
antihypertensive therapy has been associated with 35–40 percent reductions in stroke 
incidence [Chobanian et al, 2003].  
Ohira et al (2006) studied a cohort of more than 14 000 men and women aged 45 to 64 years 
(free of clinical stroke) from the ARIC study (Atherosclerosis Risk in Communities), who 
were followed during an average of 13.4 years. They found that during the follow-up 
period, 531 incident ischemic strokes occurred (105 lacunar, 326 nonlacunar, and 100 
cardioembolic strokes), and hypertension was the most powerful predictor for all ischemic 
stroke subtypes. 
The evaluation of the consequences of hypertension on the heart and kidney has become a 
mainstay in routine clinical practice for years. Nevertheless, target organ damage to the brain 
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is currently a research issue, and little has been accomplished in relation to introducing 
effective and low cost evaluation methods to be used by the medical practitioner. 
3. Biomarkers for brain damage in hypertension 
During the last decade research efforts have increased trying to demonstrate subclinical 
organ damage to the central nervous system as a consequence of essential hypertension. The 
most important evidence has been obtained employing imaging techniques (MRI, CT and 
positron emission tomography), as microvascular disease results in chronic ischemic 
changes affecting mainly the white matter.  
Neuropsychological methods have demonstrated impairment of different cognitive domains 
(attention, memory, executive function) in hypertensive patients. Although the effect of anti-
hypertensive treatment on cognitive function and dementia onset is controversial, a meta-
analysis of randomized clinical trials suggested that anti-hypertensive treatment is beneficial 
for the prevention of cognitive decline, particularly in elderly high risk patients (O’Sullivan 
et al, 2003). 
Another line of investigation has been brain electrical activity in hypertension. A recent 
study in neurologically asymptomatic hypertensive patients showed that quantitative EEG 
revealed altered spontaneous brain activity, mainly in the frontal and midline regions of the 
left hemisphere, which they infer as probably associated with brain hypoperfusion (De 
Quesada, 2010). 
There is ongoing research into the association of blood pressure variability over the daytime 
and night-time periods (e.g.dipping status, early morning surge) with early brain 
deterioration in hypertension. To date it remains unknown whether and to what extent 
monitoring ambulatory blood pressure could prove useful for detecting subclinical damage 
of the central nervous system in hypertensive patients (Sierra, 2011). 
There are many published reports indicating that serum molecular markers for neuronal 
damage are useful for estimating the timing and extent of cerebral injury, as well as for long 
term clinical outcome in several conditions, such as cardiopulmonary bypass, cardiac arrest, 
stroke, traumatic brain injury and others. For many years research has been directed toward 
the identification of biomarkers for establishing the differential diagnosis, aetiology and 
prognosis, which have gone from the application of clinical scores to more complex imaging 
techniques. In between these two methods, blood based biomarkers have received an 
important attention, especially during the last decade. 
3.1 Imaging techniques 
There is strong evidence that cerebral white matter hyperintensities (WMH) in hypertensive 
patients should be considered a silent early marker of brain damage. MRI and positron emission 
tomography (PET) techniques have shown signs of hypertensive target organ damage in the 
brain of asymptomatic hypertensive patients. WMHs or leukoaraiosis have been extensively 
documented in hypertensive patients, but silent lacunar infarcts and microbleeds can also be 
found, and recently dilated Virchow-Robin spaces have been considered as indicative of vascular 
damage (Angelini et al, 2009; Kitagawa, 2010; Lindgren et al, 1997; Mancia et al, 2007). 
Hypertension is associated with the risk of subclinical brain damage noticed on cerebral 
MRI, particularly in elderly individuals. The most common types of brain lesions are WMH, 
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which can be seen in almost all elderly individuals with hypertension and silent infarcts, the 
frequency of which varies between 10% and 30% according to different studies. Both lesions 
are characterized by high signal on T2-weighted images. Another type of lesion, more 
recently identified, are microbleeds, which are seen in about 5% of individuals on MRI 
Gradient echo (GRE) T2* images (Tzourio et al, 2010). 
Several studies have suggested that sustained or uncontrolled hypertension is associated 
with a greater WMH load. The level of blood pressure also seems to play a role, higher 
blood pressure values being associated with higher grades of WMH. These dose-dependent 
effects provide strong support for a causal relationship between high BP and WMH. 
Older age and hypertension are constantly reported to be the main risk factors for cerebral 
WMH. Hypertensive patients have a higher rate and extension of cerebral WMHs compared 
with normotensives (Sierra et al, 2011). 
In humans, long term hypertension has been associated with the presence of periventricular 
and subcortical white matter lesions, and a subsequent cognitive decline has been 
demonstrated in certain settings (De Leeuw et al, 2002; Lindgren et al, 1997).  Henskens et al 
(2009) described a continuous relationship between the volume of WMHs and ambulatory BP 
levels, while successfully controlled hypertension had a lower risk of WMHs (De Leeuw et al, 
2002; Kuller et al, 2010). White matter lesions may arise from factors associated with brain 
hypoperfusion and breakdown of the blood-brain barrier, leading to decreased cerebral blood 
flow and consequent cerebral ischemia (De Leeuw et al, 2002; Henskens et al, 2009). 
The clinical significance and pathological substrate of WMH are incompletely understood. It 
is known that they are an important prognostic factor for stroke, cognitive impairment, 
dementia and death. Cerebral WMH are more common and extensive in patients with 
cardiovascular risk factors, such as hypertension and diabetes mellitus, heart disease, and 
symptomatic cerebrovascular disease (Sierra el al, 2011).  
Kitagawa  (2010) studied the association between cerebral blood flow (CBF) and cognitive decline 
in hypertensive patients. They enrolled 27 cognitively intact patients with lacunar infarction or 
cerebral white matter lesions in MRI and measured CBF and cerebral vascular reactivity (CVR) 
with PET. Their results strongly suggest that cerebral hypoperfusion is associated with later 
cognitive decline in hypertensive patients with cerebral small vessel disease. 
The pathogenesis of WMH remains unclear, but the main current hypothesis concerning the 
association between high BP and WMH is that long-standing hypertension causes 
lipohyalinosis of the media and thickening of the vessel walls, with narrowing of the lumen 
of the small perforating arteries and arterioles that nourish the deep white matter. On the 
other hand, low BP has also been reported to be a risk factor for WMH (Sierra, 2011). 
3.2 Retinal microvascular abnormalities 
The retina offers a unique, noninvasive, and easily accessible window to study the 
microvascular etiology of cerebrovascular disease. Retinal and cerebral small vessels share 
similar embryological origins, anatomical features, and physiological properties. The 
hypertensive retinal changes defined qualitatively from a fundus examination have been 
traditionally classified into four grades of retinopathy (Scheie, 1953); nevertheless, most 
hypertensive patients today present early in the process of their illness, and hemorrhages 
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and exudates (grade 3), not to mention papilloedema (grade 4), are observed very rarely. 
The milder degrees of retinopathy appear to be largely non-specific arteriolar alterations 
(Grades 1 and 2) and their usefulness for prognosis has been questioned (Mancia et al, 2007), 
except for young patients. Thus, more selective methods for objectively investigating ocular 
damage in hypertension have been developed and studied.  Digitized retinal photographs 
can be analyzed by a semiautomated program to quantify geometric and topological 
properties of arteriolar and venular trees. This method has identified hypertension-related 
topological alterations of retinal vasculature and showed that retinal arteriolar and venular 
narrowing may precede the development of hypertension (Grassi & Schmieder, 2011).  
Cheung et al (2011) provided interesting data on the quantitative and qualitative assessment 
of retinal microvascular abnormalities in a general population and their relationships with 
blood pressure values. These authors developed new quantitative parameters which 
describe the retinal branching pattern (retinal vascular branching angle, the retinal vascular 
branching asymmetry ratio and the retinal vascular fractal dimension), as well as qualitative 
parameters (focal arteriolar narrowing, arteriovenous nicking, opacification of the arteriolar 
wall and retinopathy signs). These innovative parameters allow the investigators to improve 
the sensitivity and specificity of the approach in detecting retinal microcirculatory 
alterations. 
Recently the presence of WMHs was said to be related not only to elevated brachial systolic BP, 
pulse pressure and arterial stiffness, but also to retinal arterial narrowing (Scuteri et al, 2011). 
Studies have shown that retinal microvascular flow is reduced in persons with WMH and 
lacunar infarction. In a cohort of 1684 asymptomatic people aged 51–72 years from the ARIC 
study, individuals with WMH were more likely to have retinal microvascular abnormalities 
(Sierra et al, 2011). Retinal microvascular abnormalities measured at baseline were 
prospectively associated with a long-term risk of subclinical cerebrovascular disease on 
MRI, independent of conventional risk factors in this population-based cohort of middle-
aged persons without clinical stroke. The authors suggested that retinal microvascular 
abnormalities are early and, possibly, more sensitive markers of subclinical cerebral small-
vessel disease before radiological and clinical manifestations become apparent. 
3.3 Cognitive tests 
The role of hypertension as a risk factor for cognitive impairment is known from cross-
sectional and longitudinal studies. The outcome of chronic microvascular damage is a 
continuous progression from mild cognitive alterations to overt vascular dementia. 
Semplicini et al (2011) reported the time course of cognitive changes in a cohort of long-term 
treated hypertensives, who never met the clinical criteria for dementia. At basal observation, 
the executive functions (the most affected cognitive domains) correlated with attention and 
cerebrovascular damage, but not with BP. They found that attention was positively 
correlated to BP (the higher the BP, the better attention performance). After 6-year follow-
up, attention and executive functions improved, in spite of the minor BP changes, memory 
decline and progression of cerebrovascular damage. Based on these findings they suggested 
that short-term BP lowering negatively affected executive performance through unfavorable 
effects on attention. During long-term treatment, attention improved, probably because of 
adaptation of the cerebral circulation to lower BP, and this would also account for 
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improvement of executive functions, in spite of the similar BP control and greater 
cerebrovascular damage.  
Cognitive tests may help to detect initial brain deterioration in hypertension. It has been 
established that microvascular brain damage electively and predominantly affects executive 
function, with a slower information processing, impairments in the ability to shift from one 
task to another, and deficits in the ability to hold and manipulate information (i.e., working 
memory). Ideally, neuropsychological evaluation should include tests exploring multiple 
cognitive domains (executive function and activation, language, visuospatial ability, 
memory), in addition to neurobehavioral symptoms and mood. It has been put forward that 
future clinical guidelines should make clear that cognitive impairment has to be considered 
as target-organ damage in hypertensive patients, although it has been mentioned in the 2007 
Guidelines from European Society of Hypertension (Scuteri et al, 2011).  
The mechanisms underlying hypertension-related cognitive changes are complex and are 
not yet fully understood. It has been suggested that increased BP may explain the 
deterioration in cognitive functions in hypertensive individuals involving small vessel 
disease, white-matter lesions and endothelial dysfunction. An association was encountered 
between the presence of WMH and poorer performance on neuropsychological tests in 
middle-aged, asymptomatic, never-treated essential hypertensive patients (Sierra, 2011). 
3.4 Physiological and neurophysiological methods 
3.4.1 Ambulatory blood pressure monitoring 
There is ongoing research into the association of blood pressure variability over the daytime 
and night-time periods (e.g. dipping status, early morning surge) with early brain 
deterioration in hypertension. To date it remains unknown whether and to what extent 
ambulatory blood pressure monitoring (ABPM) could prove useful for detecting subclinical 
damage of the central nervous system in hypertensive patients. 
In essential hypertension, the presence of WMH has been associated with an exaggerated 
decline in nocturnal BP; however, this finding has not been replicated in subsequent studies. 
Steady and pulsatile components of daytime, night time and 24-h BP have gained increased 
interest in the prediction of WMH, lacunar infarctions and stroke. Van Boxtel et al (2006) 
reported no association between night time dipping of BP and WMH load, whereas  daytime 
and 24-h pulse pressure averages were associated with pWMH, and systolic BP and mean 
arterial pressure for all periods were higher in patients with lacunar infarctions. They concluded 
that there was no relationship between diurnal BP rhythm and evidence of structural or 
functional cerebral damage in a population of newly diagnosed hypertensive individuals, but 
that the ABP profile may predict lesion type in early asymptomatic cerebral abnormalities. 
Although in the Japanese population, nondipping and extreme dipping have repeatedly 
been associated with silent cerebrovascular disease (WMH and lacunar infarctions), the 
consequences of diurnal BP variations on the brain remain to be elucidated in Caucasian 
populations. Several reasons have been adduced: limitations in study size; different 
considerations for lesion description; classification of dipping (no consensus on what BP 
variable to use: systolic BP, diastolic BP or mean arterial pressure); optimal cutoff values; 
presentation of data (relative dipping or dipping status); duration of hypertension and 
treatment history (Van Boxtel et al, 2006). In advanced old age, hypertension was found to 
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be associated with evidence of target-organ damage; ABPM was positively associated with 
cerebral periventricular hyperintensities on MRI, and was more effective than conventional 
BP measurement in predicting HT target-organ damage (O’Sullivan et al, 2003). 
Very recently Sierra (2011) extensively reviewed the association between ABP parameters 
and WMH, and concluded that although ABPM 24-hour values are related to the presence 
and severity of cerebral WMH, the direction of this association still remains speculative and 
that larger, longitudinal studies will be required to establish causality. 
3.4.2 Brain electrical activity 
Another line of investigation has been brain electrical activity in hypertension. A study 
conducted in neurologically asymptomatic hypertensive patients showed that quantitative 
EEG revealed altered spontaneous brain activity, mainly in the frontal and midline regions of 
the left hemisphere, which they infer as probably associated with brain hypoperfusion (De 
Quesada et al, 2005). More recently De Quesada-Martínez & Reyes Moreno (2010) investigated 
the localization of paroxysmal activity employing Low Resolution Electromagnetic 
Tomography (LORETA) in 84 patients with high BP and no history of neurological diseases. 
They found that the generators for the paroxysmal activity were mainly localized on the right 
Brodmannn´s 17 and 37 areas, and on the left Brodmannn´s 6, 39 and 10 areas. These regions 
are very sensitive to hypoperfusion caused by arterial hypertension. 
3.5 Blood biomarkers 
There are many published reports indicating that serum molecular markers for neuronal 
damage are useful for estimating the timing and extent of cerebral injury, as well as for long 
term clinical outcome in several conditions, such as cardiopulmonary bypass, cardiac arrest, 
stroke, traumatic brain injury and others (Dassan et al, 2009; Gottesman & Wityk, 2006; 
Marchi et al, 2006; Selakovic et al, 2005; Shinozaki et al, 2009).  
Nevertheless, to our best knowledge attempts to demonstrate silent brain damage in 
hypertension employing serum biochemical markers have only been made in two settings:  
1. Schmidt et al. in 2004 provided preliminary evidence demonstrating that increased 
S100B was associated with eclampsia, but not with preeclampsia or chronic 
hypertension in pregnant women, conditions very dissimilar to essential hypertension. 
They hypothesized that increased S100B could be secondary to cerebral vascular 
changes leading to overperfusion, edema, and ischemia, as well as to seizures 
themselves, although they deemed the latter less plausible. 
2. Al-Rawi and Atiyah (2009) measured salivary and serum levels of neuron specific 
enolase (NSE) in 25 hypertensive patients. Although they did not attain statistical 
significance, they observed higher mean serum NSE levels in hypertensive patients 
than in healthy controls, with values ranging between those obtained in ischemic stroke 
patients and healthy controls. The object of their study was not hypertension, and no 
associations were made with clinical variables related to the severity of hypertension. 
For decades, researchers have sought for clinically useful blood biomarkers of nervous 
system injury, and these efforts have intensified in the past few years. Although the ideal 
biomarker remains elusive, several molecules have received attention (CK-BB, glial fibrillary 
acidic protein, S100B, NSE, among others) (Laskowitz et al, 2009; Mayer & Linares, 2009). Of 
www.intechopen.com
 
Brain Damage – Bridging Between Basic Research and Clinics 88
these, NSE and S100B are the ones which have been studied most often in clinical settings 
(Dassan et al, 2009; Kleine et al, 2003; Konstantinou et al, 2008; Selakovic et al, 2005; Van 
Munster et al, 2009). NSE has been recognized in the guidelines developed by the American 
Academy of Neurology as a useful prognostic indicator in comatose patients with global 
hypoxic-ischemic brain injury. 
Following we present our experience in relation to the serum biochemical markers (NSE and 
S100B) as early predictors of brain damage in essential hypertension (González-Quevedo et 
al, 2011).  
Fifty patients with essential arterial hypertension, who had been referred by the general 
practitioner to the Department of Ophthalmology for evaluation of retinopathy were 
recruited. The hypertension status of the study sample was assessed using standard criteria 
formulated by Joint National Committee VII (Chobanian et al, 2003). The mean (±SD) age 
was 57.6±11.6 years, and 38% were males. Ninety six % of the patients had a diagnosis of 
essential hypertension that dated back from over 5 years (5 to 35 years); only 2 of them had 
less than five years of disease duration. All patients completed an interview aimed to 
ascertain their personal pathological history and medication used.  Forty seven patients 
(94%) were receiving antihypertensive drugs. Those with clinical evidence of known 
neurological disease, malignancies, chronic degenerative or inflammatory diseases, recent 
infection or trauma were not included.   
The control group was comprised of 42 apparently healthy subjects who volunteered to be 
included in this study - mean (±SD) age was 52.4±12.5 years, and 42.9% were males. 
Hypertension was excluded by clinical history and blood pressure (BP) measurement taken 
before blood extraction, no retinopathy was detected at fundoscopic examination, and no 
known history of neurological, cardiovascular, liver, renal, inflammatory or malignant 
diseases was reported. Those referring recent infection or trauma were not included.  
Before blood extraction, BP was measured in patients and controls in the right arm and in 
the seated position after a 5-min rest period, following the recommendations of Perloff et al 
(1993). Hypertensive patients were classified in four groups according to BP measurements: 
<120/80; 120-139/80-89; 140-159/90-99 and > 160/100 (Chobanian et al, 2003). Fundoscopic 
examination to evaluate hypertensive retinopathy was carried out in all patients and 
controls and they were classified according to Scheie (1953).  
Brain MRI scanning was conducted in 23 of the 50 hypertensive patients.  Both groups of 
patients (with and without MRI) had a similar composition with respect to demographic and 
clinical variables. The degree of WMH severity was rated visually on axial FLAIR images using 
the Fazekas scale (Fazekas et al, 1987), and patients were classified in two groups:  
 Group 0-I: Included Grade 0 (no hyperintense lesions) and Grade I (slight changes: only 
one lesion < 10 mm or grouped lesion areas < 20 mm for any diameter). 
 Group II-III: Included Grade II (only one hyperintense lesion from 10 – 20 mm or 
grouped hyperintense areas > 20 mm for any diameter), and Grade III (severe changes:  
confluent hyperintense areas on both sides ≥ 20 mm for any diameter). 
Lacunes were defined as hypointense foci of <3 mm on MPRAGE that were surrounded by 
white matter or subcortical gray matter and not located in areas with a high prevalence of 
widened perivascular spaces (eg, anterior commissure, vertex). The number of lacunes was 
recoded into none, few (1 to 3 lacunes), and many (4 lacunes or more).  
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Dilated Virchow Robin spaces (> 2 mm) were identified and classified in 3 groups: None (no 
dilated Virchow spaces); Few (1 to 3); Many (4 or more). 
Serum S100B and NSE were determined employing the immunoassay kits CanAg  S100 EIA 
(708-10) and CanAg  NSE EIA (420-10) from CanAg Diagnostics AB (Sweden).  
Table 2 shows the mean serum concentrations for S-100B and NSE in hypertensive patients 
and controls. Both proteins displayed significantly higher levels in patients with respect to 
controls, while no differences were detected with gender and age. No correlation was 
observed between NSE and S-100B levels. 
 
Serum proteins 
Control      
n=42 
Hypertension 
n=50 
Student´s        
t- test 
P 
S-100B (ng/L) 72.3 ± 29.5 108.6 ± 53.1 t = 3.944 p = 0.0002 
NSE (µg/L) 8.6 ± 4.2 12.5 ± 7.9 t = 2.749 p = 0.002 
Table 2. Mean ± SD of serum S-100B and NSE levels in controls and hypertensive patients 
 
 
HT: hypertension 
Results for Kruskal-Wallis test shown in the figure.  
Pos hoc analysis for S-100B: HT + retinopathy vs control (p=0.0003) 
Pos hoc analysis for NSE: HT + retinopathy vs HT no retinopathy (p=0.02) 
HT + retinopathy vs control (p=0.01) 
Fig. 1. Scatter plot of serum S-100B (A) and NSE (B) concentrations in controls and 
hypertensive patients with and without retinopathy.  
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Diastolic BP (DBP), but not systolic BP (SBP) taken immediately before blood extraction 
correlated with NSE levels (r=0.325, p = 0.023), while no correlation was found between  
S-100B concentration and SBP or DBP.  
When patients were classified as having or not having retinopathy and compared with 
controls (Figure 1), higher NSE and  S-100B levels were found to be associated with the 
presence of retinopathy (p=0.0004 and p=0.0022 respectively). For NSE a significant increase 
was demonstrated in patients exhibiting retinopathy with respect to those without 
retinopathy (p=0.029), while for S-100B, a similar tendency was observed, but it did not 
reach statistical significance. It should be pointed out that hypertensive patients without 
retinopathy displayed serum S-100B and NSE concentrations (means: 83 and 6.3 
respectively) very similar to controls (means: 72.3 and 8.6 respectively). 
The association with the grade of retinopathy could be further confirmed when patients were 
distributed according to NSE and S100B cut off levels. Figure 2 shows how the frequency of 
patients with NSE>14 μg/L and S100B>130 ng/L significantly increased with the grade of 
retinopathy. The X2 test was conducted considering two groups of retinopathy: lower severity 
(0 – I) and higher severity (II – III) to avoid empty cells. It is noteworthy that NSE>14 μg/L and 
S100B>130 ng/L were not observed in hypertensive patients without retinopathy. 
 
NSE: χ2=6.766, p=0.009; S100B: χ 2=5.347, p=0.021 
Fig. 2. Percentage of patients with increased serum NSE and S100B levels according to grade 
of retinopathy. 
The independent variables included in the multivariate regression analysis (SBP, DBP, grade 
of retinopathy and years of hypertension), with NSE as the dependent variable, fitted the 
whole generalized regression model (multiple R=0.547; F=4.335, p=0.005). NSE was 
independently associated with diastolic blood pressure and grade of retinopathy, but not 
with systolic blood pressure and duration of hypertension; whereas no associations were 
observed for S-100B. 
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As brain MRI scans were performed in 23 of the hypertensive patients, the results were 
evaluated with respect to NSE and S-100B levels (Table 3). Distribution of the patients 
according to the Fazekas Scale revealed some degree of WMHs in 17 (73.9%), while only 6 
patients displayed no hyperintense lesions (Grade 0). Eight patients classified as Grade I, 
seven as Grade II and 2 patients as grade III. Non parametric statistical analysis assembling 
Grades 0-I and Grades II-III, showed that patients with more severe WMHs had higher 
serum NSE levels than those with no hyperintensities or slight changes (p < 0.05), while S-
100B levels did not differ. Hyperintensities were not associated with other risk factors 
(smoking, alcohol, diabetes).  
Dilated Virchow Robin spaces and lacunes were detected in 11 and 5 patients respectively.  
No significant differences for S-100B or NSE levels were encountered when analyzing the 
presence of dilated Virchow spaces or of lacunes. 
 
Brain MRI variables n S-100B (ng/L) NSE (µg/L) 
WMH 
(Fazekas scale) 
Grades 0 - I 14 
124.3 
(53.2 – 210.4) 
10.6 
(3.9 – 16.4) 
Grades II - 
III 
9 
107.0 
(53.6 – 215.3) 
20.6 * 
(4.3 - 29.3) 
Dilated Virchow   Robin 
spaces 
None 12 
117.0 
(53.2 – 151.0) 
9.1 
(4.3 – 20.2) 
Few 1 121.7 12.3 
Many 10 
114.8 
(63.7 – 241.3) 
16.1 
(4.6 – 28.8) 
Presence of lacunes 
None 18 
131.1 
(53.2 – 215.3) 
13.3 
(3.9 – 28.3) 
Few 5 
103.8 
(73.8 – 121.7) 
12.3 
(4.9 – 20.6) 
Many 0 - - 
WMH: white matter hyperintensities 
Medians and 10-90 percentiles of NSE and S-100B are presented 
* Mann-Whitney U test:  Z = 1.980, p= 0.049 (Fazekas scale 0-I vs II-III) 
Table 3. Brain MRI variables and serum concentrations of S-100B and NSE in hypertensive 
patients.  
To rule out the effect of antihypertensive treatment on blood levels of S-100B and NSE, two 
analyses were carried out: 1) effect of one or two antihypertensive drugs vs joint 
administration of more than two drugs (polytherapy) and 2) effect of individual groups of 
antihypertensive drugs (ACE inhibitors, calcium channel blockers, ǃ-blockers, diuretics).  
No significant differences were observed when patients treated with polytherapy were 
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compared with those receiving one or two drugs. None of the individual groups of 
antihypertensive drugs increased the serum concentrations of S-100B and NSE. 
3.5.1 Discussion of blood markers in hypertension 
In the present study we examined the status of serum NSE and S-100B in patients with 
essential arterial hypertension, and their possible implication as early markers of brain 
damage. We found that both markers were significantly higher in hypertensive patients 
than in controls and the multivariate analysis revealed that NSE was independently 
associated with two variables expressing severity of hypertension: diastolic blood pressure 
(but not systolic) and grade of retinopathy; while S-100B was not associated with any of the 
clinical variables analyzed. Furthermore, seeking for a neuroanatomical support to the 
serum concentration of these brain specific proteins, brain MRI studies performed in a 
group of hypertensive patients, denoted a relationship between increased serum NSE levels 
(but not S-100B) and more severe white matter lesions. This is the first study demonstrating 
raised NSE levels related to severity in essential hypertension, and suggesting that it may be 
a marker of early brain damage accompanying the hypertensive syndrome.  
MRI and positron emission tomography (PET) techniques have shown signs of hypertensive 
target organ damage in the brain of asymptomatic hypertensive patients as we explained 
with more details in previous sections of this chapter. Although this study is limited by the 
fact that brain MRI could only be performed in half of the cohort, a relationship between 
increased serum NSE levels and severity of WMHs was observed.  
The fact that NSE and S-100B are elevated in hypertensive patients with respect to controls 
does not necessarily denote early signs of brain damage. It is important to take into account 
that although S100B and NSE are highly specific for brain tissue, they are also expressed in 
other cell types under physiological and pathological conditions. S-100B is found in 
adipocytes, bladder and colon cells, and elevated serum levels have been reported in 
patients with bone fractures, thoracic contusions, burns and melanoma (Dassan et al, 2009; 
Kleine et al, 2003). NSE is also present in erythrocytes and platelets; while high serum levels 
have been reported with malignant tumors such as neuroblastomas, small cell carcinoma of 
the lung and seminomas (Kleine et al, 2003; Shinozaki et al, 2009). Although the issue of 
contamination of these serum proteins with extracerebral sources was strictly controlled in 
this study, it cannot be absolutely ruled out.  
Our results indicate that NSE is independently associated with the severity of hypertension 
(specifically expressed through increased DBP and the grade of retinopathy) and the brain 
MRI studies suggest that NSE increase could be in relation to the severity of white matter 
lesions. The fact that non-nervous tissue NSE content is so low with respect to brain that it is 
not liable to increase serum levels - with the exception of malignancies of the 
neuroendocrine system and some other tumors (Kleine et al, 2003) -, could point to a certain 
degree of silent brain damage in a subset of hypertensive patients. 
In the case of S-100B, the lack of association with variables related to the severity of 
hypertension after multivariate analysis, and with MRI findings, strongly suggests that this 
increase is probably not originating in the nervous system. Nevertheless, this issue remains 
an open question that should be addressed in the future.   
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An additional cause leading to elevation of S-100B and NSE could have been the 
antihypertensive treatment that more than 90% of the patients were receiving. Nevertheless, 
the analysis carried out indicates that no specific group of antihypertensive drugs was 
associated with increased serum S-100B or NSE in our study, nor did we find any reference 
in the literature in this respect.    
Our results provide preliminary evidence suggesting that raised NSE and S100B could be 
the result of silent brain damage in a group of hypertensive patients; however, inflammation 
is an important coexisting factor that must be considered, especially in the case of S100B, 
where no clear association could be established with severity of hypertension or of WMHs. 
The possibility that increased NSE and/or S100B could be related to the systemic 
inflammatory process clearly demonstrated in hypertension cannot be ruled out, and will be 
the object of future work in our laboratory.  
Since the observation made by Sesso et al in 2003 that increasing levels of C-reactive protein 
were associated with an increased risk of developing hypertension, scientists have been 
trying to unravel the mechanisms linking chronic low-grade systemic inflammation with 
high blood pressure. Independent associations between inflammatory biomarkers (C-
reactive protein, interleukins 6 and 18, tumor necrosis factor-) and measures of arterial 
stiffness and wave reflections (Schnabel et al, 2008; Vlachopoulos et al, 2010) and in essential 
hypertension (Bautista et al, 2005) have been established. 
There are some reports linking S100B with inflammation. Depending on its concentration, 
S100B has two opposing effects, trophic and toxic. At nanomolar concentrations, S100B 
stimulates neurite outgrowth and enhances survival of neurons. However, at micromolar 
concentrations, S100B stimulates the expression of proinflammatory cytokines such as IL-6 
and induces apoptosis (Steiner et al, 2011).  
In experimental animals, overproduction of S100B in the astrocytes of stroke-prone 
spontaneously hypertensive rats has been demonstrated, while treatment with arundic acid 
prevented hypertension-induced stroke and inhibited the enlargement of the stroke lesion 
by preventing the inflammatory changes caused by overproduction of the S100B protein in 
the astrocytes (Higashino et al, 2009). On the other hand, in a clinical setting, the degree of 
systemic inflammation was found to be associated with S100B concentration in acute 
ischemic stroke, independent of the size of the ischemic lesion (Beer et al, 2010).  
Very recently Steiner et al (2011) provided solid evidence showing that CD3+ CD8+ T cells 
and CD3¯ CD56+ NK cells express S100B, and that stimulated CD8+ T cells release S100B 
which could lead to activation of granulocytes and monocytes. This could indicate a novel 
regulatory mechanism of innate immune functions by S100B+ T cells distinct from cytokine- 
and chemokine-mediated pathways. Due to the emerging role of S100B as an interface with 
the immune system, the results provide the ground for a wide array of future studies in 
physiological and pathological conditions that have been associated with increased S100B 
levels (Steiner et al, 2011). 
Thus, the association of raised S100B levels in hypertensive patients –where low level chronic 
inflammation has been well established- could gain new meaning in view of the above 
described and formerly unknown close interactions between S100B and the immune system. 
Overall, at this point all these considerations are hypothetical and require additional research. 
www.intechopen.com
 
Brain Damage – Bridging Between Basic Research and Clinics 94
In conclusion, in the present study we have shown that serum NSE and S-100B are elevated 
in hypertensive patients, and furthermore that NSE (but not S-100B) is associated with the 
severity of hypertension and white matter lesions. Our findings provide for the first time 
preliminary evidence suggesting that raised NSE could be the result of silent brain damage 
in a subset of hypertensive patients. Additional research is needed involving larger cohorts, 
more sensitive imaging techniques and the use of other biochemical, electrophysiological 
and neurocognitive methods in order to consistently confirm this hypothesis. 
4. Conclusion  
Contrary to the subclinical detection of cardiovascular and renal target organ damage, 
which is very well established in clinical practice for the management of hypertension, brain 
target organ damage to date has no readily available technique to be used by the medical 
practitioner. From the evidence previously presented, it is obvious that at this moment, the 
only method that can be reliably employed for this purpose is brain MRI. Nevertheless, MRI 
is not as widely accessible as it would be needed, to screen such a highly prevalent disease, 
and is furthermore, very costly. On the other hand, it should be taken into account that 
several studies have alerted on the high frequency of subclinical brain target organ damage, 
as compared to cardiorenal damage. Thus there is no doubt that the search for effective, less 
expensive and available methods is urgently required. In this respect blood biomarkers of 
brain damage are a promising and practically unexplored avenue that needs to be more 
deeply investigated. 
What could be the clinical relevance of our preliminary findings? The use of serum S-100B 
and NSE as early and quantitative markers could prove important as a potential tool in the 
hands of clinicians for the detection and prevention of initial brain deterioration in 
hypertensive patients. On the other hand, the longitudinal study of this cohort could also 
offer important information on their usefulness as prognostic factors.  
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"Brain Damage - Bridging Between Basic Research and Clinics" represents a collection of papers in an attempt
to provide an up-to-date approach to the fascinating topic of brain damage in different pathological situations,
combining the authors' personal experiences with current knowledge in this field. In general, the necessary link
between basic and clinical neurosciences is highlighted, as it is through this interaction that the theoretical
understanding of the pathophysiological mechanisms can be successfully translated into better ways to
diagnose, treat and prevent the catastrophic events that occur when the brain suffers from external or internal
noxious events. The book spans different aspects of brain injury, starting from damage occurring in the fetal
and child brain, followed by different neurodegenerative processes. Attention is also focused on the negative
effects of drug addictions and sleep deprivation on the brain, as well as on the early assessment of brain injury
for preventive strategies employing sensitive biomarkers.
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